Astellas Signs DAX-044 Immuno-Oncology License Deal Worth Up to $1.34 Billion
Astellas Pharma and Audax Biosciences announced an exclusive option and license agreement for Audax’s DAX-044 immuno-oncology candidate, with potential deal value of up to $1.34 billion.